Thymic carcinoma is a rare and aggressive cancer that arises from the epithelial cells of the thymus, a small organ behind the breastbone that plays a role in immune development during childhood. It accounts for roughly a fifth of all thymic cancers in the United States, with an age-standardized incidence of about 0.07 per 100,000 people, and it behaves far more aggressively than its more common cousin, thymoma. Because the thymus sits deep in the chest and shrinks naturally with age, thymic carcinoma often grows silently for months before anyone notices, making diagnosis and treatment a genuine challenge.
How Common Is It, and Who Gets It
Thymic cancers as a group are uncommon, but thymic carcinoma is the rarer subcategory within an already rare disease. In a U.S. database spanning 2001 to 2015, researchers identified 13,586 patients with thymic cancer. Of those, about two-thirds had thymoma and roughly 20% had thymic carcinoma. The incidence of thymic carcinoma rose over that period, climbing from 0.03 per 100,000 in 2001 to 0.07 per 100,000 in 2015, an average annual increase of about 5.3%.1PLoS ONE. Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States Some of that increase likely reflects improvements in imaging technology and diagnostic awareness rather than a true surge in the disease itself.
The pattern is not the same everywhere. In South Korea, a country with generally higher rates of thymic tumors, thymic carcinoma made up 38% of all thymic epithelial tumors, nearly double the U.S. proportion. The Korean age-standardized incidence rate for thymic carcinoma was 0.18 per 100,000, with an annual percentage increase of about 7%.2PubMed. Trends in Incidence and Survival of Patients With Thymic Epithelial Tumor in a High-Incidence Asian Country Whether this geographic difference stems from genetics, diagnostic practices, or environmental factors remains unclear.
Peak incidence occurs in people in their 60s and 70s, though thymic carcinoma can show up at any age. Unlike many cancers, common environmental exposures such as tobacco, alcohol, radiation, and diet do not appear to play a significant role. There is some limited evidence linking thymic tumors to viral infections, including Epstein-Barr Virus, but this connection is not firmly established.3PubMed Central. Epidemiology of thymoma
Symptoms and How It Gets Found
Many people with thymic carcinoma have no symptoms at all in the early stages. The tumor sits in the anterior mediastinum, the space between the lungs behind the sternum, where it can grow to a substantial size before pressing on anything important. When symptoms do appear, they tend to be local: chest pain, a persistent cough, and shortness of breath are the most common complaints. If the tumor invades surrounding structures, more alarming problems can develop, including superior vena cava syndrome, a condition where the tumor compresses the large vein returning blood from the upper body to the heart. That causes swelling of the face, neck, and arms, and it typically signals advanced disease.4PubMed Central. Thymic carcinoma and superior vena cava syndrome: Case report
One important distinction from thymoma is the relationship with autoimmune conditions. Thymoma is famously associated with myasthenia gravis and other paraneoplastic syndromes because the abnormal thymic tissue continues to churn out immune cells that attack the body’s own tissues. Thymic carcinoma, by contrast, has largely lost the architecture of normal thymic tissue. Its cells look and behave more like a conventional cancer than like dysfunctional thymus, so autoimmune paraneoplastic syndromes are far less common. This difference matters for diagnosis: a mediastinal mass in someone with myasthenia gravis points toward thymoma, while an aggressive-looking mass without autoimmune symptoms raises more concern for thymic carcinoma.
Imaging and Initial Workup
Contrast-enhanced CT is the go-to imaging study for evaluating any thymic mass. It reliably shows the tumor’s location, size, shape, density, and whether it is invading nearby structures like the pericardium, great vessels, or lungs. CT is generally equal or superior to MRI for mediastinal masses, with the caveat that MRI is better at distinguishing cystic components from solid tissue and can help evaluate the extent of local invasion in ambiguous cases.5PubMed Central. Imaging evaluation of thymic tumors MRI also has a niche role in telling apart thymic tumors from thymic hyperplasia using chemical shift sequences that detect microscopic fat.
PET/CT adds value when the tumor appears aggressive or when there is concern about distant spread. Thymic carcinomas tend to be more metabolically active on PET than thymomas, though there is overlap. Pleural metastases, which are more common with thymic carcinoma, show up as small enhancing nodules or areas of thickened pleura on thin-slice CT, but PET and MRI can help in borderline cases.6PubMed Central. Imaging evaluation of thymic tumors
The Diagnostic Puzzle Under the Microscope
Once tissue is obtained, the pathologist faces a genuinely difficult job. Squamous cell carcinoma is the most prevalent subtype of thymic carcinoma.7PubMed Central. Factors distinguishing thymomas from thymic squamous cell carcinoma: a proposal for diagnosis emphasizing the immunophenotype Under the microscope, thymic squamous cell carcinoma can look strikingly similar to squamous cell carcinoma that started in the lung and spread to the mediastinum. It can also overlap with type B3 thymoma, the most aggressive thymoma subtype, making the boundary between advanced thymoma and frank carcinoma blurry.8PubMed Central. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas
To sort this out, pathologists rely on immunohistochemical stains, essentially antibody-based markers that light up specific proteins in the tumor. Two markers have proven especially useful for confirming thymic origin:
- CD117 (c-Kit): Positive in roughly 70–84% of thymic carcinomas but in only about 20–27% of lung squamous cell carcinomas.
- CD5: Positive in about 53–70% of thymic carcinomas and essentially absent in lung carcinomas.
When both CD117 and CD5 are positive, the tumor is almost certainly thymic in origin. In one study, every tumor that stained positive for both markers turned out to be thymic carcinoma, and the vast majority of tumors negative for both were lung cancers.9PubMed. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors A separate study confirmed CD117 positivity in 84% of thymic carcinomas versus about 27% of lung carcinomas, and CD5 positivity in 53% of thymic carcinomas versus 0% of lung carcinomas.10PubMed. Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma
Distinguishing thymic carcinoma from type B3 thymoma is a separate challenge. A marker called GLUT-1, a glucose transporter protein, has emerged as particularly helpful here, with 72% sensitivity and 100% specificity for thymic carcinoma over B3 thymoma. When GLUT-1 is combined with CD5 and CEA, the panel can differentiate thymic carcinoma from B3 thymoma with over 91% sensitivity and 100% specificity.11Modern Pathology. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma No single marker is perfect on its own, though, so pathologists typically use panels of several stains to reach a confident diagnosis.12Journal of Clinical and Experimental Hematopathology. The Evaluation of Immunohistochemical Markers and Thymic Cortical Microenvironmental Cells in Distinguishing Thymic Carcinoma from Type B3 Thymoma or Lung Squamous Cell Carcinoma
Genomic Landscape
Unlike some cancers where a single “driver” mutation dominates (think EGFR in certain lung cancers or BRAF in melanoma), thymic carcinoma’s genomic profile is defined by the loss of tumor-suppressor genes rather than the activation of clear therapeutic targets. The most commonly altered genes are CDKN2A (found in about 38–40% of cases), TP53 (30–37%), and CDKN2B (about 25–31%), according to data from both U.S. and Japanese genomic databases.13PubMed Central. Genomic characterization of thymic epithelial tumors in a real-world dataset Other recurrently altered genes include KIT, CYLD, TET2, SETD2, BAP1, ASXL1, and FGFR3.14PubMed Central. Genomic insights into molecular profiling of thymic carcinoma: a narrative review
Mutations in TP53 and loss of the protein encoded by CDKN2A (called p16) are both tied to worse outcomes, including earlier recurrence and shorter survival.15PubMed Central. Genomic insights into molecular profiling of thymic carcinoma: a narrative review Sequencing studies have also detected mutations in genes like FGFR3 and KIT, which are at least potentially targetable with existing drugs, though clinical evidence for precision-targeted therapy in thymic carcinoma is still thin.16PubMed Central. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets The lack of a single dominant actionable mutation is one reason treatment development has been slow for this disease.
Staging and What It Means for Prognosis
Two staging systems coexist for thymic tumors, which can be confusing. The older Masaoka-Koga system, based on the degree of capsular invasion and spread, has been used for decades and remains widely applied. The newer TNM system, developed by the International Association for the Study of Lung Cancer and the International Thymic Malignancies Interest Group, aims to provide more granular separation. Both systems agree on the broad strokes: tumors confined to the thymus do best, and widely metastatic disease does worst.
In a large Chinese database study, early Masaoka-Koga stage, complete (R0) resection, and postoperative radiation were all independently associated with better survival.17PubMed. Long-Term Survival After Surgical Treatment of Thymic Carcinoma Under the TNM system, patients with the most localized disease (T1a) had significantly lower recurrence rates than all other categories, while T4 disease carried the worst survival.18PubMed Central. Comparison of the Masaoka-Koga staging and the International Association for the Study of Lung Cancer/the International Thymic Malignancies Interest Group proposal for the TNM staging systems Neither system perfectly stratifies intermediate stages, and studies have noted overlapping survival curves between some adjacent stage groups with both systems.19PubMed Central. Masaoka-Koga and TNM Staging System in Thymic Epithelial Tumors: Prognostic Comparison and the Role of the Number of Involved Structures
Surgery as the Cornerstone
Complete surgical removal remains the single most important treatment for thymic carcinoma whenever it is feasible. The data here are consistent across multiple large retrospective studies: achieving a complete resection with clear margins (R0) is the strongest predictor of long-term survival. In a Japanese nationwide study of 306 surgically treated patients, R0 resection was associated with the greatest survival benefit. Even incomplete resections (R1 or subtotal R2) produced better survival than no resection at all, reinforcing the value of attempting surgery even when clear margins seem unlikely.20European Journal of Cardio-Thoracic Surgery. Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study
A separate analysis from a tertiary care center found median overall survival of 125 months after R0 resection, compared with just 25 months for R1 and 24 months for R2 resections. Intraoperative tumor spillage also significantly shortened survival.21Nepalese Journal of Cancer. Long term survival and prognostic factors for Thymoma and Thymic carcinoma The practical takeaway is that surgical technique and tumor handling matter enormously in a disease where the difference between a clean resection and a compromised one can translate to years of additional life.
Radiation and Chemotherapy
Postoperative radiation therapy is commonly recommended after thymic carcinoma surgery, particularly when margins are close or positive, or when the disease is at an advanced stage. A large international database analysis found that postoperative radiation, along with lower pathologic stage and R0 resection, was independently associated with improved overall survival.22PubMed. Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database Expert consensus recommends conventional daily fractionation to a dose of 45 to 60 Gy in the postoperative setting and 60 to 66 Gy when radiation is used as the primary treatment in patients who cannot undergo surgery. Elective treatment of uninvolved lymph nodes is generally considered unnecessary.23JAMA Oncology. American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma
Proton therapy, which deposits radiation more precisely than conventional photon beams, has shown promising early results. In a prospective study, patients treated with proton therapy achieved 100% local control at two years of follow-up, with no grade 3 or higher toxicity. The most common side effect was mild skin inflammation.24Radiotherapy and Oncology. Proton therapy for thymic tumors The tumor’s location between the heart and lungs makes limiting radiation to surrounding healthy tissue especially important, and proton therapy’s dose profile may offer advantages in that regard.
For advanced or recurrent disease, platinum-based chemotherapy has been the traditional backbone. The combination of carboplatin and paclitaxel is commonly used, though response rates are modest. In one study of relapsed thymic carcinoma patients treated with this regimen, the response rate was 25%, with a disease control rate (including stable disease) of about 58%. Median progression-free survival was only about 3.5 months.25PubMed Central. Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma These numbers underscore the limitations of conventional chemotherapy for this disease and the need for better systemic options.
Newer Drugs and Their Tradeoffs
Two newer classes of drugs have generated cautious optimism. The multi-kinase inhibitor lenvatinib, which targets blood vessel growth and several other signaling pathways, was tested in a phase 2 trial of 42 previously treated patients with advanced thymic carcinoma. The response rate was 38%, with another 57% achieving stable disease.26The Lancet Oncology. Lenvatinib for advanced or metastatic thymic carcinoma (REMSTART) Those numbers are substantially better than traditional chemotherapy and have positioned lenvatinib as a leading option in the relapsed setting.
Immune checkpoint inhibitors, particularly pembrolizumab, have also been tested. In a single-center phase 2 trial, pembrolizumab produced responses in about 22.5% of thymic carcinoma patients, with one complete and eight partial responses among 40 patients. More than half achieved at least stable disease.27PubMed Central. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study A separate trial showed similar results, with a 19% response rate among 26 thymic carcinoma patients.28PubMed. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
There is a real catch with immunotherapy in this disease, though. Because the thymus is the organ responsible for educating the immune system, cancers arising from it carry a uniquely elevated risk of autoimmune side effects when the immune brakes are released. In the single-center pembrolizumab trial, 15% of patients developed severe autoimmune toxicity, including myocarditis, a potentially life-threatening inflammation of the heart muscle. Several patients required hospitalization and high-dose steroids.29The Lancet Oncology. Pembrolizumab in patients with advanced thymic carcinoma (PEMBRO-THYM) The rate of severe immune-related side effects is notably higher in thymic carcinoma than in other tumor types where checkpoint inhibitors are routinely used, demanding close monitoring from oncology teams who prescribe them.
How and Where It Spreads
When thymic carcinoma recurs or metastasizes, the pattern differs from thymoma. Thymoma tends to stay in the chest, particularly along the pleural surfaces. Thymic carcinoma is significantly more likely to spread to distant sites, including the lungs, liver, bone, and even the brain.30PubMed Central. Comparison of Patterns of Relapse in Thymic Carcinoma and Thymoma In one study comparing relapse patterns, 60% of thymic carcinoma recurrences occurred at distant sites, versus only 13% for thymoma.
Recurrence also tends to happen faster. The median time from surgery to disease progression was about 9 months for thymic carcinoma, compared with 20 months for thymoma.31PubMed Central. Comparison of Patterns of Relapse in Thymic Carcinoma and Thymoma A larger imaging review reported a similar finding: median time to recurrence or metastasis was about 25 months for thymic carcinoma versus nearly 69 months for high-risk thymomas.32PubMed Central. Patterns of metastasis and recurrence in thymic epithelial tumours In the setting of metastatic or recurrent disease, the most common sites of involvement are serosal surfaces (the lining of the chest and abdomen), followed by the lungs, lymph nodes, bone, and liver.33PubMed. Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy
Survival and the Factors That Shape It
Overall five-year survival for thymic carcinoma varies considerably depending on stage at diagnosis and whether the tumor can be completely removed. For advanced disease (Masaoka stage III or IV), five-year progression-free and overall survival rates were about 24% and 36% in one long-term follow-up study. Elevated blood levels of lactate dehydrogenase, advanced T stage, and higher pathologic grade were all independently associated with worse outcomes.34PubMed Central. Long-term follow-up and prognostic factors for advanced thymic carcinoma When all stages are combined, five-year survival estimates for thymic carcinoma generally fall in the range of 36–60%, depending on the population studied and how many patients had resectable disease.35Nepalese Journal of Cancer. Long term survival and prognostic factors for Thymoma and Thymic carcinoma
These numbers are far less favorable than for thymoma, where five-year overall survival exceeds 85–90% in many series. The gap reflects thymic carcinoma’s greater tendency to invade locally, metastasize to distant sites, and resist systemic treatments. Early Masaoka-Koga stage, complete resection, and the use of postoperative radiation consistently emerge as the three factors most strongly associated with longer survival across studies from multiple countries and time periods.
Thymic Carcinoma in Young Patients
Thymic carcinoma is predominantly a disease of older adults, but it does occasionally occur in younger people, including adolescents. A national cohort analysis looking at pediatric, adolescent, and young adult patients identified 193 thymic carcinoma cases within a broader group of 1,069 thymic epithelial tumors. Five-year survival for thymic carcinoma in this younger population was 36%, compared with 87% for thymoma. Thymic carcinoma was associated with a nearly threefold increase in the risk of death even after adjusting for stage and treatment. Strikingly, outcomes were significantly worse for pediatric and adolescent patients compared to young adults, a difference not observed for thymoma.36PubMed Central. Thymic epithelial tumors in pediatric, adolescent, and young adult patients The reasons for this age-related disparity in thymic carcinoma are not fully understood, but it may relate to biological differences in tumors that develop during active thymic function versus those that arise after the gland has involuted.
Surgery was strongly protective in this younger cohort, reinforcing the central importance of resection at any age. The finding that chemotherapy was associated with worse survival likely reflects confounding: patients who received chemotherapy tended to have more advanced disease that was not amenable to surgery alone.